News MannKind Corporation

Equities

MNKD

US56400P7069

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
4.08 ^USD	-0.49%		-5.12%	+12.09%

Mar. 26	MannKind CFO Binder to Retire in April, Names New CFO	MT
Mar. 26	MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MannKind Repays Certain Debt Obligations	Apr. 03	AQ
MannKind CFO Binder to Retire in April, Names New CFO	Mar. 26	MT
MannKind Announces CFO Transition	Mar. 26	AQ
MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024	Mar. 26	CI
MannKind Corporation Appoints Steven B. Binder as Executive Vice President, Special Projects	Mar. 26	CI
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps	Mar. 11	AQ
MannKind Corporation Announces INHALE-3 Study?s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections and Insulin Pumps	Mar. 11	CI
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8	Mar. 05	AQ
MannKind Corporation Announces Participation at Upcoming Conferences	Mar. 04	AQ
Transcript : MannKind Corporation, Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Earnings Flash (MNKD) MANNKIND Reports Q4 Revenue $58.5M, vs. Street Est of $53.1M	Feb. 27	MT
MannKind Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update	Feb. 27	AQ
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024	Feb. 20	AQ
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®	Feb. 15	AQ
MannKind Corporation Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®	Feb. 15	CI
Transcript : MannKind Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 11:15 AM	Jan. 11
MannKind Announces Up To $200 Million Royalty Purchase Agreement With Sagard Healthcare	Jan. 09	AQ
Transcript : MannKind Corporation - Special Call	Jan. 03
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday	Jan. 02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News MannKind Corporation

Equities

MNKD

US56400P7069

Summary

Filters